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Abstract 
Leydig cell tumour is a benign testicular non-germ cell tumour, and malignant 
transformation is rare. We report a case of a 35-year-old man who came to our hospital 
with a painless left testicular mass measuring 1.2 × 1 cm. Histological evaluation of the 
tumour showed features of a malignant Leydig cell tumour but no infiltration beyond the 
capsule or metastasis. The small size of the tumour was remarkable. 
 
Introduction 
Leydig cell tumours are rare stromal tumours of the testis accounting for 1–3% of 
testicular neoplasms. About 10% of them are malignant. They exhibit a peak incidence in 
the preadolescent as well as in the older (>50 years) age groups [1–4]. The diagnosis of a 
malignant Leydig cell tumour is not always easy since no definite histological criteria for 
malignancy exist. 
Case Report 
A 35-year-old man presented to our hospital with a 3-month history of a painless left testicular mass. 
He had no gynaecomastia. Blood concentrations of chorionic gonadotrophin, fetoprotein and human 
placental lactogen were within the reference range. Physical examination and ultrasonography revealed 
a testicular mass measuring 1.2 × 1 cm. A left radical orchidectomy was performed and the specimen 
submitted for histopathological examination. On microscopic examination, a malignant Leydig cell 
tumour was found. The cells displayed acidophilic cytoplasm, intranuclear inclusions and increased  
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mitotic activity (>3/10 HPF). Many cells with large atypical pleomorphic nuclei could also be observed 
(fig. 1, fig. 2). There was no angiolymphatic invasion, foci of necrosis or extension beyond the capsule 
of the testis. The immunohistochemical study showed that the tumour cells were positive for vimentin, 
melan A and inhibin, and negative for CKAE1, CKAE3, S100p, P63, CEA, AFP and actin. Ki67 was 
expressed in 10% of the malignant cells (fig. 3). 
Retroperitoneal lymph node dissection was suggested, but the patient declined further surgery. One 
year later, he showed no evidence of metastasis. 
Discussion 
Leydig cell tumours are rare and only about 3% of them are bilateral. About 15–20% of 
the patients already present with metastatic disease, particularly in the lymph nodes, lung 
and liver [5]. These tumours may be hormonally active, and gynaecomastia is seen in 30% 
of the cases [2, 3, 6]. 
Leydig cell tumours in an undescended testis may exhibit only manifestation of 
endocrinological disorders such as gynaecomastia, impotence and loss of libido. However, 
among the 480 cases of Leydig cell tumours reported in the literature, only 20 cases were 
associated with cryptorchidism, and there is no evidence that undescended testes are 
more prone to develop Leydig cell tumours [2, 5, 7]. Features associated with malignancy 
include a large tumour size (5.7 cm), nuclear atypia, a mitotic count of >3/10 HPF, foci of 
necrosis, angiolymphatic invasion, infiltrative margins, DNA aneuploidy and an 
increased expression of Ki67/MIB-1 and p53 [2, 3, 8–10].  
Our patient was young and did not fit into either of the known age incidence peaks. 
Microscopic features such as the severe nuclear atypia and increased mitotic activity 
(>3/10 HPF) favoured the diagnosis of malignancy. However, there was no 
angiolymphatic invasion or extension beyond the capsule of the testis. Also, the small size 
of the tumour was remarkable. One year after surgery, the patient was well with no 
evidence of metastasis. 
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Fig. 1. Malignant cell tumour. Nuclear and cellular polymorphism and abnormal mitoses. ×400. 
 
 
 
Fig. 2. Malignant Leydig cell tumour. ×200. 
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Fig. 3. Immunohistochemical staining for inhibin A. ×400. 
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